Home › Compare › IVIXF vs EQR

IVIXF vs EQR: Dividend Comparison 2026

IVIXF yields 5420.05% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IVIXF wins by $136326195118802.19M in total portfolio value
10 years
IVIXF
IVIXF
● Live price
5420.05%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$136326195118802.23M
Annual income
$131,551,666,493,773,860,000.00
Full IVIXF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — IVIXF vs EQR

📍 IVIXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIVIXFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IVIXF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IVIXF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IVIXF
Annual income on $10K today (after 15% tax)
$460,704.61/yr
After 10yr DRIP, annual income (after tax)
$111,818,916,519,707,770,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, IVIXF beats the other by $111,818,916,519,707,770,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IVIXF + EQR for your $10,000?

IVIXF: 50%EQR: 50%
100% EQR50/50100% IVIXF
Portfolio after 10yr
$68163097559401.14M
Annual income
$65,775,833,246,886,930,000.00/yr
Blended yield
96.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

IVIXF
No analyst data
Altman Z
-30.2
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IVIXF buys
0
EQR buys
0
No recent congressional trades found for IVIXF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIVIXFEQR
Forward yield5420.05% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$136326195118802.23M ✓$47.8K
Annual income after 10y$131,551,666,493,773,860,000.00 ✓$5,475.61
Total dividends collected$136003983287005.17M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: IVIXF vs EQR ($10,000, DRIP)

YearIVIXF PortfolioIVIXF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$552,705$542,005.42$11,380$679.82+$541.3K → IVIXF
2$28,588,529$27,997,133.96$13,014$837.25+$28.58M → IVIXF
3$1,383,995,048$1,353,405,322.61$14,961$1,036.20+$1383.98M → IVIXF
4$62,714,057,337$61,233,182,635.19$17,297$1,289.22+$62714.04M → IVIXF
5$2,660,288,543,813$2,593,184,502,462.66$20,121$1,613.15+$2660288.52M → IVIXF
6$105,651,330,702,723$102,804,821,960,842.73$23,561$2,030.84+$105651330.68M → IVIXF
7$3,928,761,972,612,137$3,815,715,048,760,222.50$27,783$2,573.54+$3928761972.58M → IVIXF
8$136,812,745,737,264,320$132,608,970,426,569,340.00$33,013$3,284.39+$136812745737.23M → IVIXF
9$4,462,176,285,073,260,500$4,315,786,647,134,387,700.00$39,547$4,223.51+$4462176285073.22M → IVIXF
10$136,326,195,118,802,240,000$131,551,666,493,773,860,000.00$47,791$5,475.61+$136326195118802.19M → IVIXF

IVIXF vs EQR: Complete Analysis 2026

IVIXF — Stock

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.

Full IVIXF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this IVIXF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IVIXF vs SCHDIVIXF vs JEPIIVIXF vs OIVIXF vs KOIVIXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.